Both tests offer cancer variant detection services based on a validated oncology panel. The interrogated genes and genomic alterations of the panel are the same. Similarly, the techniques used for both products are based on hybridisation for target enrichment and next-generation sequencing.
The two products differ in their starting material. INVIEW Oncoprofiling can accept conventional source material like fresh-frozen and FFPE tissues, whereas INVIEW Liquid Biopsy Oncoprofiling analyses cfDNA extracted from blood plasma samples.